Obesity rarely travels alone. Sleep apnea, GERD, cardiovascular risk, joint disease, metabolic syndrome — these conditions are common travel companions, and many of them respond directly to the weight loss journey. Real information on what the research shows and what we're experiencing firsthand.
These are not GLP-1 pages. They're not peptide pages. They're conditions — diagnoses that often come with obesity and that often improve, sometimes dramatically, when the weight comes off. The sections here are built on real clinical data, peer-reviewed research, and personal experience. Some will be ongoing BriteBriefs — living documents that get updated as the journey continues and new data comes in. Not medical advice — educational.
What severe OSA actually looks like — AHI 98, O₂ nadir 76%, zero REM. How CPAP changed everything the same night. What three years of data shows. And what GLP-1 weight loss appears to be doing to the underlying disease.
Gastroesophageal reflux disease and its relationship to obesity and the GLP-1 journey. Including what the research shows about GLP-1's effect on reflux, and what surgical repair options look like.
The SELECT trial. What GLP-1 therapy does to cardiovascular outcomes independently of weight loss. Heart rate, blood pressure, inflammation markers, and what the data means for people on the journey.
Insulin resistance, blood pressure, triglycerides, HDL. The cluster of conditions that travel together and that GLP-1 therapy addresses on multiple fronts simultaneously.
The TRIUMPH-4 retatrutide data showed 75.8% reduction in knee pain scores. But weight loss alone has measurable effects on joint load and inflammation. What the research shows — and what Cheryl's bilateral knee replacement journey adds to it.
More conditions will be added as research is reviewed and personal data becomes available. This section grows with the journey.